Definition:Genetic testing
🧬 Genetic testing refers to medical analyses that identify changes in chromosomes, genes, or proteins, and its intersection with insurance raises some of the most complex underwriting, ethical, and regulatory questions the industry faces today. In life insurance and health insurance, genetic test results could theoretically help underwriters assess an applicant's predisposition to conditions such as hereditary cancers, cardiovascular disease, or neurological disorders. However, the use of such information in insurance decisions has become one of the most heavily debated and regulated areas in global insurance markets, touching on fundamental tensions between actuarial precision and societal fairness.
⚖️ Regulatory approaches to genetic testing in insurance vary dramatically across jurisdictions. In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits health insurers from using genetic information in coverage and pricing decisions, though it notably does not extend to life, disability, or long-term care insurance. The United Kingdom operated for years under a voluntary moratorium — the Concordat and Moratorium on Genetics and Insurance — under which insurers agreed not to require or use predictive genetic test results for most policies, with a narrow exception for Huntington's disease in high-value life policies; this was replaced by a binding Code on Genetic Testing and Insurance in 2018. In several Continental European markets, laws outright ban the use of genetic data in insurance underwriting. Countries such as Canada enacted legislation — the Genetic Non-Discrimination Act — that broadly prohibits insurers from requiring genetic test results, although legal challenges have tested its constitutional boundaries. In contrast, some Asian markets have yet to establish comprehensive frameworks, leaving the question to evolving industry practice and regulatory guidance.
🔍 The significance of genetic testing for the insurance industry extends beyond current regulation into strategic territory. As direct-to-consumer genetic testing services have proliferated, the problem of adverse selection looms large: applicants who learn of elevated genetic risks may seek higher coverage without disclosing those results, while those receiving favorable results may reduce coverage — creating an information asymmetry that distorts risk pools. Actuaries and policy experts continue to study the potential magnitude of this effect, particularly in life and long-term care lines. For insurers, the challenge lies in balancing sound risk assessment practices with evolving social expectations around genetic privacy, all while navigating a patchwork of national laws that show no signs of harmonizing in the near term.
Related concepts: